A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.

Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A
Clin Cancer Res. 2015 21 (7): 1566-73

PMID: 25573383 · PMCID: PMC6607903 · DOI:10.1158/1078-0432.CCR-14-2820

MeSH Terms (18)

Aged Antineoplastic Agents Carcinoma, Squamous Cell Chemoradiotherapy Cisplatin ErbB Receptors Female Head and Neck Neoplasms Histone Deacetylases Humans Hydroxamic Acids Male Maximum Tolerated Dose Middle Aged Quinazolines Radiotherapy Receptor, ErbB-2 Squamous Cell Carcinoma of Head and Neck

Connections (1)

This publication is referenced by other Labnodes entities: